Cargando…

Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83–100 Gy in five fractions

We previously reported that the local control of pulmonary metastases from colorectal cancer (CRC) following stereotactic body radiotherapy (SBRT) with moderate prescription dose was relatively worse. We investigated the treatment outcomes and toxicities of patients with oligometastases from CRC tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeda, Atsuya, Sanuki, Naoko, Tsurugai, Yuichiro, Oku, Yohei, Aoki, Yousuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Regular Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973648/ https://www.ncbi.nlm.nih.gov/pubmed/26983981 http://dx.doi.org/10.1093/jrr/rrw029

Ejemplares similares

Stereotactic body radiotherapy for patients with non-small-cell lung cancer using RapidArc delivery and a steep dose gradient: prescription of 60% isodose line of maximum dose fitting to the planning target volume
por: Tsurugai, Yuichiro, et al.
Publicado: (2019)

Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume
por: Takeda, Atsuya, et al.
Publicado: (2014)

Role of stereotactic body radiotherapy in multidisciplinary management of liver metastases in patients with colorectal cancer
por: Sanuki, Naoko, et al.
Publicado: (2022)

Relationship between Dose Prescription Methods and Local Control Rate in Stereotactic Body Radiotherapy for Early Stage Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis
por: Eriguchi, Takahisa, et al.
Publicado: (2022)

Applying Artificial Neural Networks to Develop a Decision Support Tool for Tis–4N0M0 Non–Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy
por: Nemoto, Takafumi, et al.
Publicado: (2022)

Three Cases of Hepatocellular Carcinoma With Massive Macrovascular Invasion Successfully Treated With Radiotherapy
por: Tsurugai, Yuichiro, et al.
Publicado: (2021)

Stereotactic body radiotherapy for T3 and T4N0M0 non–small cell lung cancer
por: Eriguchi, Takahisa, et al.
Publicado: (2016)

Multi-Institutional Outcomes of Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy With a Median Biologically Effective Dose of 100 Gy(10) for Non-bone Oligometastases
por: Kutuk, Tugce, et al.
Publicado: (2022)

Stereotactic body radiotherapy for primary non-small cell lung cancer patients with clinical T3-4N0M0 (UICC 8th edition): outcomes and patterns of failure
por: Narita, Atsuya, et al.
Publicado: (2019)

Stereotactic radiotherapy for lung oligometastases
por: Falcinelli, Lorenzo, et al.
Publicado: (2022)

Stereotactic radiotherapy for liver oligometastases
por: Menichelli, Claudia, et al.
Publicado: (2022)

Stereotactic radiotherapy for adrenal oligometastases
por: Borghesi, Simona, et al.
Publicado: (2022)

Stereotactic radiotherapy for bone oligometastases
por: Colosimo, Caterina, et al.
Publicado: (2022)

Stereotactic radiotherapy for brain oligometastases
por: Lupattelli, Marco, et al.
Publicado: (2022)

Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases†
por: Yamashita, Hideomi, et al.
Publicado: (2016)

Stereotactic body radiotherapy for chronic obstructive pulmonary disease patients undergoing or eligible for long-term domiciliary oxygen therapy
por: Hara, Yu, et al.
Publicado: (2016)

Stereotactic radiotherapy for oligometastases in the lymph nodes
por: Pasqualetti, Francesco, et al.
Publicado: (2022)

Stereotactic Radiosurgery for Vestibular Schwannomas: Reducing Toxicity With 11 Gy as the Marginal Prescribed Dose
por: Dupic, Guillaume, et al.
Publicado: (2020)

Radiation-induced rib fracture after stereotactic body radiotherapy with a total dose of 54–56 Gy given in 9–7 fractions for patients with peripheral lung tumor: impact of maximum dose and fraction size
por: Aoki, Masahiko, et al.
Publicado: (2015)

Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma – benchmark for a prospective multi-institutional study
por: Eriguchi, Takahisa, et al.
Publicado: (2013)

Harmonization of dose prescription for lung stereotactic radiotherapy
por: Beldjoudi, Guillaume, et al.
Publicado: (2022)

Feasibility of split-course stereotactic ablative radiotherapy for oligometastases
por: Paik, Eun Kyung, et al.
Publicado: (2018)

Stereotactic Ablative Radiation Therapy for Unresectable Colorectal Oligometastases
por: Sutera, Philip, et al.
Publicado: (2018)

Stereotactic Radiotherapy for Oligometastases in Lymph Nodes—A Review
por: Matsushita, Haruo, et al.
Publicado: (2018)

Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases
por: Mazzola, Rosario, et al.
Publicado: (2019)

Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases
por: Kalinauskaite, Goda G., et al.
Publicado: (2020)

Dose gradient impact on equivalent dose at 2 Gy for high dose rate interstitial brachytherapy
por: Hannoun-Levi, Jean-Michel, et al.
Publicado: (2012)

Low dose 100 cGy irradiation as a potential therapy for pulmonary hypertension
por: Egan, Pamela C., et al.
Publicado: (2019)

Impact of magnetic resonance-guided versus conventional radiotherapy workflows on organ at risk doses in stereotactic body radiotherapy for lymph node oligometastases
por: Werensteijn-Honingh, Anita M., et al.
Publicado: (2022)

Single-fraction 34 Gy Lung Stereotactic Body Radiation Therapy Using Proton Transmission Beams: FLASH-dose Calculations and the Influence of Different Dose-rate Methods and Dose/Dose-rate Thresholds
por: van Marlen, Patricia, et al.
Publicado: (2022)

Stereotactic Radiotherapy for Pulmonary Oligometastases From Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Jingu, Keiichi, et al.
Publicado: (2018)

Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes
por: Wang, Huan-Huan, et al.
Publicado: (2016)

Stereotactic Body Radiation Therapy in Gynecologic Oligometastases: An Effective but Underutilized Approach
por: Sherwani, Zohaib, et al.
Publicado: (2023)

Brachytherapy in a Single Dose of 10Gy as an “in situ” Vaccination
por: Jarosz-Biej, Magdalena, et al.
Publicado: (2020)

Flattening filter free VMAT for a stereotactic, single‐dose of 30 Gy to lung lesion in a 15‐min treatment slot
por: Pokhrel, Damodar, et al.
Publicado: (2020)

Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review
por: Almaghrabi, Mohammed Yahia, et al.
Publicado: (2012)

Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)
por: Habl, Gregor, et al.
Publicado: (2017)

Analyses of local control and survival after stereotactic body radiotherapy for pulmonary oligometastases from colorectal adenocarcinoma
por: Yamamoto, Takaya, et al.
Publicado: (2020)

Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival
por: Yamamoto, Takaya, et al.
Publicado: (2020)

Elective nodal dose of 60 Gy or 50 Gy in head and neck cancers: A matched pair analysis of outcomes and toxicity
por: Murthy, Vedang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nvebb7jiqdcltdsnhs2d18ead5